NextPlat is trying to become a contracted pharmacy platform rather than a shrinking Florida retail dispenser with a satellite catalog attached. The second quarter is the first period in which that mix shift produced near breakeven results instead of another large operating hole. Sequential sales recovered and the quarterly net loss fell to $0.1 million. Whether that print is a new run rate or a one-quarter mix accident is the entire investment debate.
The mechanism is mix, not volume. Retail prescription sales kept shrinking on weaker reimbursement and fewer fills. Contracted pharmacy work rose to $2.2 million from a much smaller year-ago base. Healthcare gross margin reached about 46 percent as covered-entity fulfillment replaced low-spread retail scripts. Both operating segments posted segment profit. Corporate overhead and a professional-fee spike still absorbed most of that segment profit, so the parent remains a holding-company problem sitting on top of two now-profitable lines.
Eleven new contracted entities signed in the first half still sit mostly in the onboarding queue, and a Pensacola-area cash purchase of Scott's Pharmacy remains unclosed. Cash of almost $12 million covers the check and the remaining burn, but a Delaware class-action accrual and an unused at-the-market facility sit next to that cash. Does the pipeline convert into sustained parent-level profit before reimbursement, litigation, or dilution reassert themselves?